|
|
Signal
transduction for proliferation of glioma cells in vitro occurs predominantly
through a protein kinase C-mediated pathway
Baltuch GH, Yong
VW
Department of Neurology and Neurosurgery, Montreal Neurological Institute,
McGill University, Quebec, Canada
Previous work has demonstrated that glioma cells have very high protein kinase C
(PKC) enzyme activity when compared to non-malignant glia, and that their PKC
activity correlates with their proliferation rate.
The purpose of this study was
to determine whether the elevated PKC activity in glioma is secondary to an
autonomously active PKC isoform implying oncogenic transformation, or whether
this activity is driven by upstream ligand-receptor tyrosine kinase
interactions.
We treated established human glioma cell lines A172, U563 or U251
with either the highly selective PKC inhibitor CGP 41 251, or with genistein, a
tyrosine kinase inhibitor.
The proliferation rate and PKC activity of all the
glioma lines was reduced by CGP 41 251; the IC50 values for inhibiting cell
proliferation corresponded to the IC50v values for inhibition of PKC activity.
Genistein also inhibited cell proliferation, with IC50 proliferation values
approximating those for inhibition of tyrosine kinase activity in cell free
protein extracts.
Importantly, in genistein-treated cells, downstream PKC enzyme
activity was dose dependently reduced such that the correlation coefficient for
effects of genistein on proliferation rate and PKC activity was 0.92.
These
findings suggest that upstream tyrosine kinase linked events, rather than an
autonomously functioning PKC, result in the high PKC activity observed in glioma.
Finally, fetal calf serum (FCS) evoked a strong mitogenic effect on glioma cell
lines.
This mitogenic activity was completely blocked by CGP 41 251, suggesting
that although the many mitogens in FCS for glioma cells signal initially through
genistein-inhibitable tyrosine kinases, they ultimately channel through a PKC-dependent
pathway.
We conclude that proliferative signal transduction in glioma cells
occurs through a predominantly PKC-dependent pathway and that selectively
targeting this enzyme provides an approach to glioma therapy.
PMID: 8963653 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8963653&dopt=Abstract
|